A meeting is being held tonight to discuss innovations in regenerative medicines, which have the potential to cure central nervous system and neurological diseases such as traumatic brain injury.
Dr Allen Davidoff, vice president of product development at Stem Cell Therapeutics Corporation (SCT) will be moderating the meeting and panel discussions, which are part of a public forum discussing Demystifying Innovations and Advancing the Commercialisation of Alberta's Emerging Technologies in regenerative medicine.
The meeting is to be held in Calgary, Canada, but the conclusions reached could have an impact on treatment of brain injury patients in the UK.
SCT is a public biotechnology company and its programs aim to repair brain and nerve function lost due to disease or injury through the development of therapies that use drugs to stimulate a patient's own resident stem cells.
The company's lead program, NTx-265, uses two approved and marketed drugs targeting the treatment of stroke. The drugs stimulate growth and differentiation of new neurons to replace the brain cells that are lost or damaged by the stroke.
On Saturday (November 28th), the Alberta Council of Technologies (ABCtech) and BioAlberta will co-host a second, similar public forum.
Serious Law, award winning traumatic brain injury solicitors. 